Who we are
Diversity and Inclusion
Penta ID Network
Penta Foundation Italy
Penta ID Innovation
News & Events
Penta Aperitivo Webinars
Work with us
Call for services
Brighter Future Award
Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children. concise Communication.
Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.
A Model-based approach to dose selection in early pediatric development
Immunologic and viral dynamics among HIV-infected children after planned treatment interruption: a substudy of the Paediatric European Network for Treatment of AIDS (PENTA) 11 trial.
PENTA and IMPAACT: A phase II/III randomised, open-label trial of combination antiretroviral regimens and treatment-switching strategies in HIV-1-infected antiretroviral naïve children
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years
Response to Planned Treatment Interruptions in HIV-infection varies across Childhood in the PENTA 11 Trial